BioLife Solutions Inc (NASDAQ:BLFS) CEO Sells $159,300.00 in Stock

Share on StockTwits

BioLife Solutions Inc (NASDAQ:BLFS) CEO Michael Rice sold 10,000 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $15.93, for a total value of $159,300.00. Following the completion of the transaction, the chief executive officer now directly owns 185,014 shares of the company’s stock, valued at approximately $2,947,273.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Michael Rice also recently made the following trade(s):

  • On Thursday, October 17th, Michael Rice sold 10,000 shares of BioLife Solutions stock. The shares were sold at an average price of $16.26, for a total value of $162,600.00.
  • On Wednesday, September 11th, Michael Rice sold 14,571 shares of BioLife Solutions stock. The shares were sold at an average price of $19.36, for a total value of $282,094.56.
  • On Monday, September 9th, Michael Rice sold 14,000 shares of BioLife Solutions stock. The shares were sold at an average price of $19.43, for a total value of $272,020.00.
  • On Thursday, August 15th, Michael Rice sold 9,905 shares of BioLife Solutions stock. The shares were sold at an average price of $18.07, for a total value of $178,983.35.
  • On Tuesday, August 13th, Michael Rice sold 9,000 shares of BioLife Solutions stock. The shares were sold at an average price of $17.07, for a total value of $153,630.00.

NASDAQ:BLFS opened at $16.33 on Friday. The stock has a market cap of $339.15 million, a P/E ratio of 116.64 and a beta of 1.35. The company has a current ratio of 9.42, a quick ratio of 7.71 and a debt-to-equity ratio of 0.02. The stock’s 50-day moving average is $18.16 and its 200-day moving average is $17.80. BioLife Solutions Inc has a 1-year low of $9.15 and a 1-year high of $22.44.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.02. The company had revenue of $6.70 million for the quarter, compared to analysts’ expectations of $6.59 million. BioLife Solutions had a return on equity of 8.65% and a net margin of 14.60%. As a group, equities analysts forecast that BioLife Solutions Inc will post 0.08 EPS for the current year.

Large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. bought a new stake in shares of BioLife Solutions during the second quarter worth about $30,000. Alpine Woods Capital Investors LLC bought a new stake in shares of BioLife Solutions during the second quarter worth about $170,000. Morgan Stanley grew its holdings in shares of BioLife Solutions by 17.5% during the second quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock worth $195,000 after purchasing an additional 1,713 shares during the last quarter. Menta Capital LLC bought a new stake in BioLife Solutions in the second quarter valued at approximately $202,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in BioLife Solutions in the second quarter valued at approximately $283,000. Institutional investors own 45.05% of the company’s stock.

A number of research firms have issued reports on BLFS. HC Wainwright began coverage on BioLife Solutions in a research report on Monday, July 22nd. They issued a “buy” rating and a $23.00 target price on the stock. Maxim Group set a $26.00 target price on BioLife Solutions and gave the company a “buy” rating in a research report on Tuesday, September 17th. BidaskClub upgraded BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Friday. Northland Securities lifted their target price on BioLife Solutions from $18.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday, September 4th. Finally, ValuEngine cut BioLife Solutions from a “hold” rating to a “sell” rating in a research report on Saturday, October 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. BioLife Solutions currently has a consensus rating of “Buy” and a consensus target price of $19.33.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

See Also: What is the Stochastic Momentum Index (SMI)?

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

$0.98 Earnings Per Share Expected for Tapestry Inc  This Quarter
$0.98 Earnings Per Share Expected for Tapestry Inc This Quarter
Teva Pharmaceutical Industries Ltd  Receives $9.76 Average Price Target from Analysts
Teva Pharmaceutical Industries Ltd Receives $9.76 Average Price Target from Analysts
Niobio Cash  Price Reaches $0.0006 on Major Exchanges
Niobio Cash Price Reaches $0.0006 on Major Exchanges
MinexCoin Hits One Day Volume of $64,893.00
MinexCoin Hits One Day Volume of $64,893.00
Minereum Trading Down 8.4% Over Last Week
Minereum Trading Down 8.4% Over Last Week
Myokardia Inc  Receives $80.50 Consensus Price Target from Analysts
Myokardia Inc Receives $80.50 Consensus Price Target from Analysts


 
© 2006-2019 Zolmax.